We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The letter follows an April Senate Finance Committee hearing during which a senior HHS official testified the department had not pressed drugmakers on why they hiked the price of naloxone. Read More
In a new attempt to prod action by HHS to lower the price of the opioid-reversing drug naloxone, Sen. Claire McCaskill (D-Mo.) asked HHS Secretary Alex Azar what the department has done since she grilled another HHS official on the issue earlier this year. Read More
A Massachusetts court Wednesday ruled in favor of Janssen in a lawsuit that claimed the Johnson and Johnson subsidiary’s antipsychotic Risperdal (risperidone) caused excessive weight gain. Read More
The Senate this week unanimously passed legislation that would forbid insurers and pharmacy benefit managers from imposing “gag clauses” on drug prices. Read More
“In order to make medicines more affordable for patients, we must address the role hospital markups play in driving up medicine costs,” said PhRMA CEO Stephen Ubl. Read More
PhRMA released a new report Wednesday highlighting the role of U.S. hospitals in increasing drug costs, showing they mark up prices for patients by an average of nearly 500 percent. Read More
The FDA issued new guidance for sponsors of drugs designed to treat hay fever as well as other cold-like symptoms that aren’t caused by allergies. In a pair of final guidances released Wednesday, the agency urges drug sponsors to focus on real-world settings when trying to determine ideal doses. Read More